Eric FRANCOIS, Dr
Centre Antoine Lacassagne, Nice
4
4
4
N/A
0
1
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (4)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Yves BECOUARN, Dr
Institut Bergonié Bordeaux
Shared therapeutic areas:
Worked with same sponsors:
Cédric LECAILLE, Dr
Polyclinique Bordeaux Nord Aquitaine-BORDEAUX
Shared therapeutic areas:
Worked with same sponsors:
Driffa MOUSSATA, Dr
Centre hospitalier Lyon Sud-PIERRE BENITE
Shared therapeutic areas:
Worked with same sponsors:
Julien FORESTIER, Dr
Hôpital Edouard Herriot-LYON
Shared therapeutic areas:
Worked with same sponsors:
Jaafar BENNOUNA, Dr
Centre René Gauducheau
Shared therapeutic areas:
Worked with same sponsors:
Hervé PERRIER, Dr
Hôpital Saint Joseph
Shared therapeutic areas:
Worked with same sponsors:
Emmanuel MAILLARD, Dr
CHR Annecy
Shared therapeutic areas:
Worked with same sponsors:
Eric TERREBONNE, Dr
Hôpîtal haut Lévèque
Shared therapeutic areas:
Worked with same sponsors:
Christophe BORG, Pr
Hôpital Andre Boulloche-MONTBELIARD
Shared therapeutic areas:
Worked with same sponsors:
Marie-Pierre GALAIS, Dr
Centre Francois Baclesse-CAEN
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (4)
Showing 4 of 4 trials
Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
All 4 trials loaded